Vaxcyte reports up to $500M common stock offering

Vaxcyte reports up to $500M common stock offering

Vaxcyte Commences $500 Million Public Offering of Common Stock and Warrants
SAN CARLOS, Calif. — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine development company, has announced the commencement of an underwritten public offering of $500 million in common stock and pre-funded warrants. The company has also granted underwriters a 30-day option to purchase up to an additional $75 million in shares, subject to market conditions and regulatory approvals.

The offering, which relies on a shelf registration statement automatically effective on May 24, 2024, will be governed by a preliminary prospectus supplement to be filed with the Securities and Exchange Commission (SEC). A final prospectus will outline the terms of the offering, including pricing and distribution details. Investors may access the prospectus materials via the SEC's website or directly from the underwriters, including BofA Securities, Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities according to the announcement.

Vaxcyte plans to use the proceeds for general corporate purposes, including advancing its pipeline of pneumococcal conjugate vaccines (PCVs) and other infectious disease candidates. The company's lead programs include VAX-31, a 31-valent PCV in Phase 3 trials for adults and Phase 2 trials for infants, and VAX-24, a 24-valent PCV designed to cover more serotypes than currently available infant vaccines. Additional candidates in development include VAX-XL, VAX-A1 (for Group A Strep), and VAX-GI (for Shigella).

The offering underscores Vaxcyte's strategy to expand its vaccine portfolio using its proprietary XpressCF® cell-free protein synthesis platform, licensed from Sutro Biopharma. This technology aims to streamline the production of complex antigens, potentially accelerating vaccine development timelines.

As of February 24, 2026, the offering remains subject to market conditions, and no guarantees exist regarding its completion or final terms. Investors are advised to review the SEC filings for detailed risk factors and offering specifics.

Source: Vaxcyte, Inc. (2026). Press release: Vaxcyte announces commencement of proposed public offering of common stock and warrants. Retrieved from https://www.stocktitan.net.